http://www.fpnotebook.com/
Mefloquine
- Indications
- Prophylaxis or Treatment of Malaria
- Preferred agent in Chloroquine resistance areas
- Contraindications
- History of Epilepsy (Seizure disorder)
- History of psychiatric disorder
- Concomitant Beta Blocker use
- Pharmacokinetics
- Half-life: 33 days
- Steady state reached
- Weekly dose: 7 weeks
- Loading dose: 4 days
- Adverse Effects
- Directions
- Take with food and full glass of water
- Dosing: Prophylaxis
- Protocol
- Start dosing 1 week before exposure
- Complete dosing 4 weeks after exposure
- Adult
- Mefloquine 228 mg base (250mg salt) PO once weekly
- Child
- Weight <15 kg
- Dose: 4.6 mg/kg base (5 mg/kg salt) PO once weekly
- Weight 15-19 kg
- Mefloquine 1/4 tablet PO once per week
- Weight: 20-30 kg
- Mefloquine 1/2 tablet PO once per week
- Weight: 31-45 kg
- Mefloquine 3/4 tablet PO once per week
- Weight: >45 kg
- Mefloquine 1 tablet PO once per week
- Weight <15 kg
- Protocol
- Dosing: Treatment
- Adult: 1250 mg for 1 dose
- Child: 15 mg/kg for 1 dose
- References
Mefloquine (C0025153) | |
|---|---|
| Definition (MSH) | A phospholipid-interacting antimalarial drug (ANTIMALARIALS). It is very effective against PLASMODIUM FALCIPARUM with very few side effects. |
| Concepts | Organic Chemical (T109) , Pharmacologic Substance (T121) |
| MSH | D015767 |
| English | Mefloquine, MEFLOQUINE PREPARATION, Mefloquine product, Mephloquine |
| Spanish | mefloquina |
| Parent Concepts | Quinolines (C0034424), Antimalarials (C0003374), Aminoquinoline antimalarial (C0360395) |
| Sources | LNC, MSH, NCI, NDFRT, RXNORM, SCTSPA, SNOMEDCT, USPMG, VANDF Derived from the NIH UMLS (Unified Medical Language System) |